Joshua Foukas compensation by year
USANA HEALTH SCIENCES Summary Compensation Table · all 4 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Salary | $471,836 | $485,991 | $487,630 | $487,630 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $568,132 | $585,164 | $731,465 | $731,477 |
| Option awards | $0 | $0 | $0 | $0 |
| Non-equity incentive | $205,673 | $73,167 | $60,661 | $35,938 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $10,150 | $10,675 | $12,985 | $13,289 |
| Total | $1,255,791 | $1,154,997 | $1,292,741 | $1,268,334 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: USANA HEALTH SCIENCES INC DEF 14A filed April 4, 2025, accession 0000896264-25-000105, and prior-year filings. Open the filing on EDGAR.
How this page was built: the USANA HEALTH SCIENCES INC filed document, accession 0000896264-25-000105. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2025.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 26,306 | $511,389 | — |
| RSU | 10,789 | $209,738 | — |
| RSU | 6,221 | $120,936 | — |
| RSU | 1,571 | $30,540 | — |
| PSU | 6,088 | — | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in USANA HEALTH SCIENCES INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
15 Form 4 lines since the FY2024 proxy (filed April 4, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-07 | Sale | — | 3,791 | $19.82 | 0 |
| 2026-02-27 | Exercise or conversion derivative | — | 6,577 | $0.00 | 66,693 |
| 2026-02-27 | Exercise or conversion | — | 6,577 | — | 6,577 |
| 2026-02-27 | Tax withholding | — | 2,786 | $21.52 | 3,791 |
| 2026-02-20 | Sale | — | 4,461 | $21.34 | 0 |
| 2026-02-19 | Grant or award derivative | — | 36,662 | $0.00 | 73,270 |
| 2026-02-08 | Exercise or conversion derivative | — | 3,597 | $0.00 | 36,608 |
| 2026-02-08 | Exercise or conversion | — | 3,597 | — | 6,047 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
USANA HEALTH SCIENCES’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Jim Brown | Chief Executive Officer & President | $3,362,107 |
| G. Douglas Hekking | Chief Financial Officer | $1,440,953 |
| Walter Noot | Chief Operating Officer | $1,438,431 |
| Brent Neidig | Chief Commercial Officer | $1,299,581 |
| Joshua Foukas · this page | Chief Legal Officer & General Counsel | $1,268,334 |
The full USANA HEALTH SCIENCES compensation record
free company briefThis page is one person within USANA HEALTH SCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the USANA HEALTH SCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are USANA HEALTH SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.